Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Management of Bilateral and Multifocal RCC: Family Matters

July 7th 2017

Gennaday Bratslavsky, MD, discusses the evaluation and management of RCC and highlighted genetic testing for the patient’s family.

Dr. Apolo on the Combination of Cabozantinib Plus Nivolumab in Urothelial Carcinoma

July 7th 2017

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the combination of cabozantinib (Cabometyx) plus nivolumab (Opdivo) in patients with urothelial carcinoma.

Dr. Rini on Adjuvant Immunotherapy in Renal Cell Carcinoma

July 6th 2017

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential of immunotherapy as an adjuvant treatment for patients with renal cell carcinoma (RCC).

It's a Family Affair

July 3rd 2017

The vision and dedication to training future urologic surgeons and advancing care by these giants of urology should never go unrecognized, underappreciated, or forgotten.

Rini Highlights Mixed Findings on Adjuvant Kidney Cancer Data

June 29th 2017

Brian Rini, MD, discusses additional adjuvant trials that have perplexed the field, what potential immunotherapy could have in this setting, and other obstacles to tackle in the renal cell carcinoma landscape.

Dr. Atkins on Results of Atezolizumab Plus Bevacizumab in RCC

June 29th 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the results of a trial of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma.

Future of Immunotherapy for GU Malignancies Goes Beyond Oncology Department

June 28th 2017

Costas Lallas, MD, discusses the current role of immunotherapy for patients with genitourinary cancers, the potential for immunotherapy in combination with chemotherapy, and how the rise of immunotherapy affects all providers treating patients with these malignancies.

Dr. Apolo on Side Effects of Cabozantinib Plus Immunotherapy Agents in Bladder Cancer

June 28th 2017

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the side effects of cabozantinib (Cabometyx) plus immunotherapy agents in bladder cancer.

Update Sustains Frontline Pembrolizumab Benefit in Urothelial Carcinoma

June 26th 2017

Updated phase II results from the KEYNOTE-052 trial showed that first-line treatment with pembrolizumab (Keytruda) produced a long-lasting response for patients with cisplatin-ineligible advanced urothelial cancer.

Expert Addresses Advances and Challenges With Immunotherapy in RCC

June 26th 2017

Moshe Ornstein, MD, discusses the obstacles physicians are facing with the use of immunotherapy for patients with renal cell carcinoma.

Tivozanib Recommended for EU Approval for RCC

June 24th 2017

The Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization of tivozanib for adult patients with advanced renal cell carcinoma.

Dr. Lara on Epacadostat Plus Pembrolizumab in RCC

June 23rd 2017

Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat plus pembrolizumab (Keytruda) in patients with metastatic renal cell carcinoma (RCC).

Frontline Pembrolizumab Approval Leaves Questions for Later Lines in Bladder Cancer

June 23rd 2017

Jorge Garcia, MD, discusses how the field of bladder cancer has transformed with the FDA approval of pembrolizumab, and how oncologists should choose between 5 checkpoint inhibitors now available for the second-line setting and beyond.

Dr. Jonasch on the Potential of Immunotherapy for Sarcomatoid RCC

June 23rd 2017

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the potential of immunotherapy for patients with sarcomatoid renal cell carcinoma (RCC).

Dr. Plimack on KEYNOTE-045 Trial for Pembrolizumab in Urothelial Carcinoma

June 22nd 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the updated findings of the KEYNOTE-045 trial of pembrolizumab (Keytruda) in urothelial carcinoma.

Split-Dose Gemcitabine and Cisplatin Shows Good Responses in Neoadjuvant MIBC

June 22nd 2017

Study results demonstrated that split-doses of gemcitabine and cisplatin as neoadjuvant chemotherapy for treating muscle-invasive bladder cancer has a good pathologic response with a high safety profile.

Dr. Garcia on FDA Approval of Pembrolizumab in Bladder Cancer

June 22nd 2017

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the May 2017 FDA approval of pembrolizumab (Keytruda) in patients with urothelial carcinoma.

Dr. Uzzo on Trials Investigating Immunotherapy in Kidney Cancer

June 22nd 2017

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice-president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses trials investigating immunotherapy in kidney cancer.

How Urology Clinics of North Texas Is Overcoming Payment Challenges

June 21st 2017

As manufacturers charge increasingly higher prices for new therapies and even well-established agents, payers have responded with pressure on practices to justify every cost, and Urology Clinics of North Texas, like many other independent practices, is caught in the middle.

Dr. Black on Sequencing of Immunotherapy in Bladder Cancer

June 21st 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses sequencing of immunotherapy for patients with bladder cancer.